Celastrol inhibits the HIF-1α pathway by inhibition of mTOR/p70S6K/eIF4E and ERK1/2 phosphorylation in human hepatoma cells

Oncology Reports

Volumn 32, Issue 1, 2014, Pages 235-242

  Ma, Juan ^a   Han, Li Zhuo ^b   Liang, He ^a   Mi, Chunliu ^a   Shi, Hui ^a   Lee, Jung Joon ^a   Jin, Xuejun ^a  

^a YANBIAN UNIVERSITY   (China)

^b Jilin Province People's Hospital   (China)

Author keywords

Antitumor; Celastrol; HIF 1 ; Translation

Indexed keywords

CELASTROL; DNA TOPOISOMERASE; ERYTHROPOIETIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; INITIATION FACTOR 4E; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; S6 KINASE; VASCULOTROPIN; TRIPTERINE; TRITERPENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOACCUMULATION; CELL GROWTH; CELL HYPOXIA; CELL LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG STRUCTURE; ENZYME PHOSPHORYLATION; FEMALE; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE TARGETING; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CARCINOMA, HEPATOCELLULAR; DRUG EFFECTS; DRUG SCREENING; EXPERIMENTAL LIVER NEOPLASM; HELA CELL LINE; LIVER NEOPLASMS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PROTEOLYSIS; TRITERPENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84903150095     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3211     Document Type: Article

References (34)

1. Harris AL: Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47, 2002.
2. Semenza GL: HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 8: S62-S67, 2002.
3. Bruick RK and McKnight SL: A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294: 1337-1340, 2001. (Pubitemid 33063099)
4. Epstein AC, Gleadle JM, McNeill LA, et al: C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 43-54, 2001. (Pubitemid 32972036)
5. Ivan M, Kondo K, Yang H, et al: HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292: 464-468, 2001. (Pubitemid 32335941)
6. 2-regulated prolyl hydroxylation. Science 292: 468-472, 2001.
7. Jeong JW, Bae MK, Ahn MY, et al: Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 111: 709-720, 2002.
8. Lu X and Kang Y: Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res 16: 5928-5935, 2010.
9. Mole DR, Blancher C, Copley RR, et al: Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts. J Biol Chem 284: 16767-16775, 2009.
10. Xia X, Lemieux ME, Li W, et al: Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proc Natl Acad Sci USA 106: 4260-4265, 2009.
11. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003.
12. Giaccia A, Siim BG and Johnson RS: HIF-1 as a target for drug development. Nat Rev Drug Discov 2: 803-811, 2003. (Pubitemid 37361812)
13. Belozerov VE and Van Meir EG: Hypoxia inducible factor-1: a novel target for cancer therapy. Anticancer Drugs 16: 901-909, 2005. (Pubitemid 41416080)
14. Salminen A, Lehtonen M, Paimela T and Kaarniranta K: Celastrol: molecular targets of thunder god vine. Biochem Biophys Res Commun 394: 439-442, 2010.
15. Hervouet E, Cizkova A, Demont J, et al: HIF and reactive oxygen species regulate oxidative phosphorylation in cancer. Carcinogenesis 29: 1528-1537, 2008.
16. Jin X, Jin HR, Lee D, Lee JH, Kim SK and Lee JJ: A quassinoid 6alpha-tigloyloxychaparrinone inhibits hypoxia-inducible factor-1 pathway by inhibition of eukaryotic translation initiation factor 4E phosphorylation. Eur J Pharmacol 592: 41-47, 2008.
17. Jin HR, Jin SZ, Cai XF, et al: Cryptopleurine targets NF-κB pathway, leading to inhibition of gene products associated with cell survival, proliferation, invasion, and angiogenesis. PLoS One 7: e40355, 2012.
18. Hagen T, Taylor CT, Lam F and Moncada S: Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1alpha. Science 302: 1975-1978, 2003. (Pubitemid 37523507)
19. Choi YK, Kim CK, Lee H, et al: Carbon monoxide promotes VEGF expression by increasing HIF-1alpha protein level via two distinct mechanisms, translational activation and stabilization of HIF-1alpha protein. J Biol Chem 285: 32116-32125, 2010.
20. Lee JH, Koo TH, Yoon H, et al: Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid. Biochem Pharmacol 72: 1311-1321, 2006. (Pubitemid 44572192)
21. Pang X, Yi Z, Zhang J, et al: Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res 70: 1951-1959, 2010.
22. Huang Y, Zhou Y, Fan Y and Zhou D: Celastrol inhibits the growth of human glioma xenografts in nude mice through suppressing VEGFR expression. Cancer Lett 264: 101-106, 2008.
23. Yang H, Chen D, Cui QC, Yuan X and Dou QP: Celastrol, a triterpene extracted from the Chinese "thunder of god vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 66: 4758-4765, 2006.
24. Laughner E, Taghavi P, Chiles K, Mahon PC and Semenza GL: HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21: 3995-4004, 2001. (Pubitemid 32476461)
25. Thomas GV, Tran C, Mellinghoff IK, et al: Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12: 122-127, 2006. (Pubitemid 43050086)
26. Hart S, Novotny-Diermayr V, Goh KC, et al: VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer. Mol Cancer Ther 12: 151-161, 2013.
27. Lachance PE, Miron M, Raught B, Sonenberg N and Lasko P: Phosphorylation of eukaryotic translation initiation factor 4E is critical for growth. Mol Cell Biol 22: 1656-1663, 2002. (Pubitemid 34174983)
28. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM and Semenza GL: Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 277: 38205-38211, 2002. (Pubitemid 35154674)
29. Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata S and Fukunaga R: Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol Cell Biol 24: 6539-6549, 2004. (Pubitemid 38944335)
30. Liu LP, Ho RL, Chen GG and Lai PB: Sorafenib inhibits hypoxia-inducible factor-1alpha synthesis: implications for anti-angiogenic activity in hepatocellular carcinoma. Clin Cancer Res 18: 5662-5671, 2012.
31. Bjornsti MA and Houghton PJ: Lost in translation: dysregulation of cap-dependent translation and cancer. Cancer Cell 5: 519-523, 2004. (Pubitemid 38748913)
32. De Benedetti A and Graff JR: eIF-4E expression and its role in malignancies and metastases. Oncogene 23: 3189-3199, 2004. (Pubitemid 38638830)
33. Wang X, Yue P, Chan CB, et al: Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation. Mol Cell Biol 27: 7405-7413, 2007. (Pubitemid 350033648)
34. Wendel HG, De Stanchina E, Fridman JS, et al: Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428: 332-337, 2004. (Pubitemid 38418805)